Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models.

ABSTRACT:

Background

Recent preclinical and clinical data suggest that leukemia inhibitory factor (LIF) is a potential target for various tumor types including pancreatic ductal adenocarcinoma as LIF is involved in multiple protumor processes including cancer stem cell maintenance, epithelial-mesenchymal transition (EMT), immunosuppression, and chemo/radioresistance. Anti-LIF antibody therapy has demonstrated safety and tolerability but limited efficacy in phase 1 clinical trial in advanced solid tumors. This prompted us to explore combination therapies, suggesting that LIF blockade, when combined with standard-of-care chemotherapy, radiotherapy, and/or immunotherapy, could present a promising therapeutic strategy.

Methods

We evaluated the impact of combining systemic inhibition of LI

SUBMITTER: Ye J 

PROVIDER: S-EPMC12067785 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature